Antiretroviral therapy coverage for PMTCT in Ecuador

Ecuador: Antiretroviral therapy coverage for PMTCT was 85.0% in 2024. ◆ Volatile

Latest (2024)
85.0%
Change on year
up 3.7%
World rank
35th
of 84 countries
All-time high
89.0%
in 2022
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Antiretroviral therapy coverage for PMTCT in Ecuador, 2000–2024

0204060802000201220242000: 0 % of pregnant women living with HIV2001: 0 % of pregnant women living with HIV2002: 5 % of pregnant women living with HIV2003: 10 % of pregnant women living with HIV2004: 15 % of pregnant women living with HIV2005: 20 % of pregnant women living with HIV2006: 25 % of pregnant women living with HIV2007: 30 % of pregnant women living with HIV2008: 32 % of pregnant women living with HIV2009: 31 % of pregnant women living with HIV2010: 34 % of pregnant women living with HIV2011: 36 % of pregnant women living with HIV2012: 39 % of pregnant women living with HIV2013: 41 % of pregnant women living with HIV2014: 43 % of pregnant women living with HIV2015: 45 % of pregnant women living with HIV2016: 47 % of pregnant women living with HIV2017: 47 % of pregnant women living with HIV2018: 48 % of pregnant women living with HIV2019: 76 % of pregnant women living with HIV2020: 60 % of pregnant women living with HIV2021: 74 % of pregnant women living with HIV2022: 89 % of pregnant women living with HIV2023: 82 % of pregnant women living with HIV2024: 85 % of pregnant women living with HIV

Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.

Analysis

The most recent figure for antiretroviral therapy coverage for pmtct in Ecuador is 85.0%, measured in 2024.

The figure is up 3.7% on the previous year and up 97.7% over ten years.

Over the whole period, antiretroviral therapy coverage for pmtct in Ecuador peaked at 89.0% in 2022 and was at its lowest, 0.0%, in 2000.

That places Ecuador 35th out of 84 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Antiretroviral therapy coverage for PMTCT in Ecuador, year by year

Annual values for Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) in Ecuador, 2000 to 2024.
Year % of pregnant women living with HIV Change
2000 0.0%
2001 0.0%
2002 5.0%
2003 10.0% +100.0%
2004 15.0% +50.0%
2005 20.0% +33.3%
2006 25.0% +25.0%
2007 30.0% +20.0%
2008 32.0% +6.7%
2009 31.0% -3.1%
2010 34.0% +9.7%
2011 36.0% +5.9%
2012 39.0% +8.3%
2013 41.0% +5.1%
2014 43.0% +4.9%
2015 45.0% +4.7%
2016 47.0% +4.4%
2017 47.0% +0.0%
2018 48.0% +2.1%
2019 76.0% +58.3%
2020 60.0% -21.1%
2021 74.0% +23.3%
2022 89.0% +20.3%
2023 82.0% -7.9%
2024 85.0% +3.7%

Ecuador compared with similar countries

  • Ecuador's 85.0% is above the median for upper middle income countries, which is 79.5%, 1.1× the median. (22 countries reporting)
  • Ecuador's 85.0% is above the median for Latin America & Caribbean, which is 68.0%, 1.2× the median. (15 countries reporting)

Biggest year-on-year movements

Years where Antiretroviral therapy coverage for PMTCT in Ecuador changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2003 +100.0% 5.0% 10.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 16.8% 0.0% 32.0% 10
2010s 45.6% 34.0% 76.0% 10
2020s 78.0% 60.0% 89.0% 5

Countries ranked near Ecuador

  1. 33 Togo 87.0% compare
  2. 34 Panama 86.0% compare
  3. 35 Vietnam 85.0% compare
  4. 37 Guyana 84.0% compare
  5. 38 Guatemala 82.0% compare
  6. 38 Mozambique 82.0% compare

See the full ranking of 99 places →

More health data for Ecuador

All data for Ecuador →

Frequently asked questions

What is antiretroviral therapy coverage for pmtct in Ecuador?
Antiretroviral therapy coverage for pmtct in Ecuador was 85.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
What is the highest antiretroviral therapy coverage for pmtct recorded in Ecuador?
The highest recorded value was 89.0% in 2022.
What is the lowest antiretroviral therapy coverage for pmtct recorded in Ecuador?
The lowest recorded value was 0.0% in 2000.
How does Ecuador rank for antiretroviral therapy coverage for pmtct?
Ecuador ranks 35th out of 84 countries with data for 2024.
Is antiretroviral therapy coverage for pmtct rising or falling in Ecuador?
Over the last ten years it is up 97.7%. The long-run trend across the full record is volatile.
Where does this Ecuador data come from?
The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Antiretroviral therapy coverage for PMTCT in Ecuador. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 17 September 2026, from https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/ecuador/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/ecuador/">Antiretroviral therapy coverage for PMTCT in Ecuador</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).